ANTI-INFLAMMATORY PEPTIDES
A polypeptide including or consisting of the amino acid sequence SEQ ID NO: 1, for use in the treatment or prevention of an inflammatory disease. A nucleic acid sequence encoding the polypeptide, a vector including the nucleic acid and a host cell including the nucleic acid sequence and/or a vector, for use in the treatment or prevention of an inflammatory disease are also described. A pharmaceutical composition including the polypeptide, the nucleic acid sequence, the vector or the host cell and a pharmaceutically acceptable carrier, for the treatment of inflammatory disease are also disclosed.
1 - 14 . (canceled)
15 . A method for preventing or treating an inflammatory disease in a patient in need thereof, said method comprising the step of administrating said patient with a therapeutically effective amount of:
i) a polypeptide comprising or consisting of the amino acid sequence SEQ ID NO:1, a conservative derivative or a fragment thereof,
ii) a nucleic acid sequence encoding the polypeptide as defined in i),
iii) a vector comprising the nucleic acid sequence as defined in ii),
iv) a host cell which has been transfected, infected or transformed by the nucleic acid sequence as claimed in ii), and/or by the vector as defined in iii).
16 . The method of claim 15 , wherein said inflammatory disease is an inflammatory bowel disease.
17 . The method of claim 15 , wherein the inflammatory bowel disease is selected in the group comprising Crohn disease, ulcerative colitis, ileitis and enteritis.
18 . The method of claim 15 , wherein said inflammatory disease is Crohn disease.
19 . The method of claim 15 , wherein said polypeptide is selected in the group comprising or consisting of the amino acid sequences SEQ ID NO:2-7.
20 . The method according to claim 15 , wherein said conservative fragment of the polypeptide is selected in the group comprising or consisting of the amino acid sequences SEQ ID NO:8-18.
21 . The method of claim 15 , wherein said polypeptide corresponds to an amino acid sequence having in the N-term to C-term orientation:
the sequence SEQ ID NO:8; and
the sequence SEQ ID NO:9,
wherein the sequence SEQ ID NO:8 and SEQ ID NO:9 are preferably spaced from 80 to 10 amino acids.
22 . The method of claim 15 , wherein said polypeptide corresponds to an amino acid sequence having in the N-term to C-term orientation:
the sequence SEQ ID NO:8; and
the sequence SEQ ID NO:9,
wherein the sequence SEQ ID NO:8 and SEQ ID NO:9 are preferably spaced from 60 to 15 amino acids.
23 . The method of claim 15 , wherein said polypeptide corresponds to an amino acid sequence having in the N-term to C-term orientation:
the sequence SEQ ID NO:8; and
the sequence SEQ ID NO:9,
wherein the sequence SEQ ID NO:8 and SEQ ID NO:9 are preferably spaced from 40 to 20 amino acids.
24 . The method of claim 15 , wherein said nucleic acid sequence encoding the polypeptide as defined in i) comprises or consists of the nucleic acid sequence defined by SEQ ID NO:19.
25 . The method of claim 15 , wherein the polypeptide comprising or consisting of the amino acid sequence SEQ ID NO:1, a conservative derivative or fragment thereof as defined in i), the nucleic acid sequence encoding the polypeptide as defined in ii), the vector as defined in iii), and/or the host cell as defined in iv) are comprised within a pharmaceutical composition, said pharmaceutical composition further comprising a pharmaceutically acceptable carrier.
26 . The method of claim 15 , wherein said inflammatory disease is an inflammatory disease resulting from an activation of the NFκB pathway.